Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Cross-bridge Cycle01:26

Cross-bridge Cycle

108.7K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
108.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

804
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
804
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

27
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
27
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

26
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Neurology. Clinical practice·2026
Same author

Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.

Therapeutic advances in neurological disorders·2026
Same author

Long-term response to deep brain stimulation of the globus pallidus internus in a patient of African origin with a homozygous DYT-AOPEP variant.

Parkinsonism & related disorders·2026
Same author

Letter to the Editor: Gastrointestinal Pseudo-Obstruction Is Not an Uncommon Phenotypic Manifestation of POLG1 Variants-Authors' Reply.

European journal of neurology·2026
Same author

Lyso-Gb3 in a Fabry pediatric cohort diagnosed by newborn screening.

Genetics in medicine open·2026
Same author

Bridging past and future: the evolution of genetic diagnosis in FSHD and the role of emerging technologies in a globalized framework.

Neuromuscular disorders : NMD·2026

Related Experiment Video

Updated: Apr 28, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.4K

Facioscapulohumeral muscular dystrophy.

Sabrina Sacconi1, Leonardo Salviati2, Claude Desnuelle1

  • 1Centre de référence des Maladies Neuromusculaires, Hôpital Archet 1, 151, route de Saint Antoine de Ginestière, 06202 Nice, France; CNRS UMR7277, Inserm U1091, iBV - Institute of Biology Valrose, UNS Université Nice Sophia-Antipolis, Faculté de Médecine, 28 Avenue Valombrose, 06189 Nice Cedex, France.

Biochimica Et Biophysica Acta
|June 3, 2014
PubMed
Summary

Facioscapulohumeral muscular dystrophy (FSHD) involves two forms, FSHD1 and FSHD2, with distinct genetic causes but similar symptoms. Both lead to DUX4 gene expression, causing muscle issues, highlighting the need for targeted therapies.

Keywords:
DNA methylationDUX4EpigeneticsFacioscapulohumeral muscular dystrophySMCHD1Subtelomeric repeat

More Related Videos

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

9.6K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.1K

Related Experiment Videos

Last Updated: Apr 28, 2026

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

33.4K
Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice
07:48

Performing Human Skeletal Muscle Xenografts in Immunodeficient Mice

Published on: September 16, 2019

9.6K
Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

6.1K

Area of Science:

  • Genetics
  • Molecular Biology
  • Neuromuscular Diseases

Background:

  • Facioscapulohumeral muscular dystrophy (FSHD) presents with characteristic muscle weakness and progresses asymmetrically.
  • Two subtypes, FSHD1 and FSHD2, share a clinical phenotype but differ in genetic and epigenetic underpinnings.
  • Both subtypes involve DUX4 gene expression, leading to muscle apoptosis and inflammation.

Purpose of the Study:

  • To elucidate the complex genetic and epigenetic factors contributing to FSHD.
  • To differentiate the molecular pathogenesis of FSHD1 and FSHD2.
  • To inform the development of novel therapeutic strategies for FSHD.

Main Methods:

  • Analysis of D4Z4 macrosatellite repeat contractions on the 4q subtelomere in FSHD1.
  • Identification of heterozygous mutations in the SMCHD1 gene in FSHD2.
  • Investigation of the role of 4qA and 4qB allelic variants in DUX4 transcript stability.

Main Results:

  • FSHD1 results from D4Z4 contraction on 4qA alleles, leading to DUX4 expression.
  • FSHD2 is a digenic disorder caused by SMCHD1 mutations and the presence of a 4qA allele.
  • Combined defects in FSHD1 and FSHD2 can result in a more severe clinical presentation.

Conclusions:

  • Understanding the distinct genetic and epigenetic mechanisms of FSHD1 and FSHD2 is crucial.
  • DUX4 expression is a common pathway in both FSHD subtypes.
  • Targeting these specific molecular defects offers potential for future FSHD therapies.